# MECLIZINE 25- meclizine hydrochloride tablet, chewable PD-Rx Pharmaceuticals, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

-----

### Meclizine 25

**Drug Facts** 

### Active Ingredients (in each chewable tablet)

Meclizine 25 mg

### Purpose

Antiemetic

### **Indications and Usage**

prevents and treats nausea, vomiting, dizziness associated with motion sickness:

### **Warnings**

• **Do not use** for children under 12 years of age unless directed by a doctor.

### Do not take unless directed by a doctor if you have

- glaucoma
- trouble urinating due to an enlarged prostate gland
- a breathing problem such as emphysema or chronic bronchitis

**Do not take if you are** taking sedatives or tranquilizers, without first consulting your doctor.

### When using this product

- do not exceed recommended dosage
- drowsiness may occur
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase drowsiness
- be careful when driving a motor vehicle or operating machinery

### If pregnant or breast-feeding,

• ask health professional before use.

### Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away. 1-800-222-1222

### **Directions**

Dosage should be taken 1 hour befor travel starts.

	Take 1 or 2
Adults and	tablets once

children 12 daily, or as years and over: directed by doctor.

### **Inactive ingredients**

Croscarmellose sodium, dextrose, FD& C Red #40, flavor, magnesium stearate, microcrystalline cellulose, silicon dioxide, sodium saccharine, stearic acid

### Questions?

Adverse drug event call (866) 562-2756 (M-F, 8AM-4PM EST).

### **How Supplied**

Meclizine 25mg are supplied as chewable pink round scored tablets with PH 051 embossed on them. Supplied in bottles of 6, 12, 20, 30 and 100 chewable tablets.

### PRINCIPAL DISPLAY PANEL - 25 mg Bottle Label

Antiemetic

Each chewable tablet contains:

Meclizine HCl

25 mg

Store at 68°-77°F (20°-25°C)

Tamper evident by foil seal under cap.

Do not use if foil seal is broken or missing.



### **MECLIZINE 25**

meclizine hydrochloride tablet, chewable

### **Product Information**

Product Type HUMAN OTC DRUG Item Code (Source) NDC:43063-804

Route of Administration ORAL

### Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength

MECLIZINE HYDRO CHLO RIDE (UNII: HDP7W44CIO) (MECLIZINE - UNII:3L5TQ84570) MECLIZINE HYDRO CHLO RIDE | 25 mg

# Inactive Ingredients Ingredient Name Strength MAGNESIUM STEARATE (UNII: 70097M6 I30) MICRO CRYSTALLINE CELLULO SE (UNII: OP1R32D6 1U) CROSCARMELLO SE SODIUM (UNII: M28 OL1HH48) DEXTRO SE (UNII: IY9 XDZ35W2) FD&C RED NO. 40 (UNII: WZB9 127 XO A) SACCHARIN SODIUM (UNII: SB8 ZUX40 TY) STEARIC ACID (UNII: 4ELV7Z65AP) SILICON DIO XIDE (UNII: ETJ7Z6 XBU4)

### **Product Characteristics**

Color	white	Score	no score
Shape	ROUND	Size	9 mm
Flavor		Imprint Code	PH;051
Contains			

P	Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
1	NDC:43063-804- 12	12 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	11/27/2017	11/30/2027	
2	NDC:43063-804- 20	20 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	0 1/12/20 18	11/30/2027	
3	NDC:43063-804- 01	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/08/2018	11/30/2027	
4	NDC:43063-804- 30	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	03/15/2018	11/30/2027	
5	NDC:43063-804- 06	6 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	07/23/2018	11/30/2027	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part336	11/27/2017	11/30/2027

# Labeler - PD-Rx Pharmaceuticals, Inc. (156893695)

## Registrant - PD-Rx Pharmaceuticals, Inc. (156893695)

Establishment				
Name	Address	ID/FEI	Business Operations	
PD-Rx Pharmaceuticals, Inc.		156893695	repack(43063-804)	

Revised: 8/2020 PD-Rx Pharmaceuticals, Inc.